Replies to post #127816 on Biotech Values

[bellweather1]

Definitely shows Ariad has learned where to put it's resources and how to rank it's prioritys in terms of advancing shareholder value.

Resolves some of the questions interested observers had up to and including the Lilly lawsuits related to the NF-kappaB pathway.

In addition to offloading development costs, new agreement gave them co-marketing opportunity to develop their sales force-

critical for advancing their other products.

So whatever else(besides signing and milestones) they get out of the Rida deal will be gravy!